JP2025504661A5 - - Google Patents
Info
- Publication number
- JP2025504661A5 JP2025504661A5 JP2024544641A JP2024544641A JP2025504661A5 JP 2025504661 A5 JP2025504661 A5 JP 2025504661A5 JP 2024544641 A JP2024544641 A JP 2024544641A JP 2024544641 A JP2024544641 A JP 2024544641A JP 2025504661 A5 JP2025504661 A5 JP 2025504661A5
- Authority
- JP
- Japan
- Prior art keywords
- sso
- composition
- sequence
- mrna
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2022/051790 | 2022-01-26 | ||
| PCT/EP2022/051790 WO2022162020A2 (en) | 2021-01-26 | 2022-01-26 | Splice switching oligonucleotides targeting pseudoexons |
| DKPA202270346 | 2022-06-29 | ||
| DKPA202270346 | 2022-06-29 | ||
| PCT/EP2023/051916 WO2023144263A1 (en) | 2022-01-26 | 2023-01-26 | Allele specific splice switching oligonucleotides targeting pseudoexons |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504661A JP2025504661A (ja) | 2025-02-14 |
| JP2025504661A5 true JP2025504661A5 (https=) | 2026-02-16 |
Family
ID=85108839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544641A Pending JP2025504661A (ja) | 2022-01-26 | 2023-01-26 | 偽エクソンを標的とする対立遺伝子特異的スプライススイッチングオリゴヌクレオチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250101419A1 (https=) |
| EP (1) | EP4469572A1 (https=) |
| JP (1) | JP2025504661A (https=) |
| CN (1) | CN119013399A (https=) |
| AU (1) | AU2023210747A1 (https=) |
| CA (1) | CA3247528A1 (https=) |
| WO (1) | WO2023144263A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024243087A2 (en) * | 2023-05-19 | 2024-11-28 | Leverna Therapeutics Inc. | Compositions and methods for regulating expression of atxn2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108603230A (zh) * | 2015-10-09 | 2018-09-28 | 南安普敦大学 | 基因表达的调节与蛋白质表达失调的筛选 |
| WO2017087282A1 (en) * | 2015-11-18 | 2017-05-26 | Rosalind Franklin University Of Medicine And Science | Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease |
| KR102318434B1 (ko) * | 2017-08-25 | 2021-11-01 | 스톡 테라퓨틱스, 인크. | 병태 및 질환 치료용 안티센스 올리고머 |
| TWI833770B (zh) * | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
| US12595479B2 (en) * | 2019-03-20 | 2026-04-07 | President And Fellows Of Harvard College | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases |
| WO2022119881A1 (en) * | 2020-12-01 | 2022-06-09 | Emendobio Inc. | Differential knockout of a heterozygous allele of lrrk2 |
| CA3204779A1 (en) * | 2021-01-26 | 2022-08-04 | Brage Storstein Andresen | Splice switching oligonucleotides targeting pseudoexons |
-
2023
- 2023-01-26 CA CA3247528A patent/CA3247528A1/en active Pending
- 2023-01-26 AU AU2023210747A patent/AU2023210747A1/en active Pending
- 2023-01-26 JP JP2024544641A patent/JP2025504661A/ja active Pending
- 2023-01-26 CN CN202380030631.5A patent/CN119013399A/zh active Pending
- 2023-01-26 WO PCT/EP2023/051916 patent/WO2023144263A1/en not_active Ceased
- 2023-01-26 US US18/728,263 patent/US20250101419A1/en active Pending
- 2023-01-26 EP EP23702114.2A patent/EP4469572A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7429318B2 (ja) | 抗ｖｅｇｆで処置された加齢黄斑変性症に罹患している患者の臨床転帰に遺伝変異型を関連付ける方法 | |
| US12571027B2 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF | |
| JP2025504661A5 (https=) | ||
| CN117795070A (zh) | 用于对elane基因进行等位基因特异性编辑的化合物和方法 | |
| US20250090690A1 (en) | Methods and systems for correcting mutations in prph2 | |
| US20250084419A1 (en) | Treatment Of Acne Rosacea With Pancreatic Lipase-Related Protein 3 (PNLIPRP3) Inhibitors | |
| US20230108957A1 (en) | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors | |
| CN1948482B (zh) | 抑制人RabJ基因表达的反义寡核苷酸序列及其应用 | |
| WO2025096087A1 (en) | Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors | |
| HK40124789A (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| WO2026036033A1 (en) | Products and methods for treatment of autosomal dominant genetic diseases involving diversified disease causing mutations | |
| WO2026015443A2 (en) | Treatment of aortic stenosis with inhibitors of alkaline phosphatase (alpl) | |
| WO2024158888A1 (en) | Treatment of stroke with 1,4-alpha-glucan-branching enzyme (gbe1) inhibitors | |
| EP4615973A1 (en) | Staufen-1 modulating agents, compositions, and methods | |
| JP2024535110A5 (https=) | ||
| US20230023182A1 (en) | Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors | |
| HK1261207B (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf | |
| HK1261207A1 (en) | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |